People who have depended on off-brand versions of Wegovy and Ozempic will likely have to pay more now that a nationwide ...

You've probably seen the ads for GLP-1 drugs. It's a hormone that helps people lose weight, but the results are not ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

The pharma giant will now offer 7.5mg and 10mg dosages of Zepbound, as well as lower rates for its 2.5mg and 5mg vials.

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...

It is bad news for telehealth company Hims & Hers Health (HIMS) today as shares plummeted after its earnings report from yesterday and some ...

Telehealth provider Hims & Hers said it will tell consumers they need to seek “alternative options on the commercial dosing,” ...

Hims & Hers will stop selling generic semaglutide after the FDA said the shortage of GLP-1 medications is resolved.

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...

Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound.